Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to demonstrate the efficacy and safety of secukinumab 150 mg or 300 mg in the management of axial manifestations in PsA patients who have failed to respond to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) over a 4-week period, according to assessment of spondyloarthritis international society (ASAS) recommendations for the treatment of axial spondyloarthritis (AxSpA).


Clinical Trial Description

In the anlalysis (CSR), there are 498 patients, as 5 patients were mis-randomized, i.e. had randomization number but did never take study medication. So there were 498 participants, and not 503 ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02721966
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 3
Start date October 3, 2016
Completion date June 26, 2019